for driving PHP over long timescales. Furthermore, unlike the other components of the PGRP pathway, Tak1 is necessary for normal functioning of the synapse, even in the absence of explicit queues that drive PHP. In the absence of Tak1, synaptic vesicles, specifically those that a primed near release sites at the plasma membrane, become depleted. Thus, it appears that this MAP kinase family member can normally tune the primed vesicle state.
These studies bring up several interesting questions. Looming largest among these is what ligands trigger the PGRP to activate PHP? Bacterial peptidoglycans are PAMP ligands for PGRP, and it is possible that PHP is triggered by bacterial pathogens. In this regard, PGRP expressed by optopaminergic neurons in Drosophila modulates their activity in regulating egg laying in response to bacterial peptidoglycans (Kurz et al., 2017) . Perhaps more likely is that PHP is regulated by DAMP-like ligands released from muscle cells at an NMJ that bind to PGRP to mediate PHP. These ligands could be released due to changes in the density of post-synaptic transmitter receptors or the size of the muscle fiber. The Davis group previously showed a ge-netic interaction between PGRP-LC and endostatin (Harris et al., 2015) , a proteolytic cleavage product of a collagen VIII that likely resides in the synaptic cleft, in driving PHP. Although PHP is generally examined in the context of genetic, disease-driven, or pharmacological impairment of postsynaptic function, the findings suggest that presynaptic function may always be tuned by muscle-derived signals that gets amplified under certain conditions. Although loss of PGRP function does not appear to impact basal transmission (Harris et al., 2015) , loss of the downstream target Tak1 does. Identifying the targets of Tak1 will likely shed important light on synaptic regulation, as it implies that the phosphorylation state of some key protein(s) controls the size of the docked and releasable synaptic vesicle pool. Similarly, it will be important to discover how Tak1 function itself is regulated and whether upstream signals other than PGRP might drive its function. Beutler, B. (2000) . Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. Curr. Opin. Microbiol. 3, 23-28. Cannon, W.B. (1929) . Organization for physiological homeostasis. Physiol. Rev. 9, 399-431.
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CHD2: One Gene, Many Roles
Vanesa Nieto-Estevez 1 and Jenny Hsieh 1, * Mutations in the chromodomain helicase DNA-binding 2 (CHD2) gene have been found in patients with a range of neurodevelopmental disorders. In this issue of Neuron, Kim et al. (2018) showed that Chd2 haploinsufficiency compromises cortical development, synaptic function, and memory in mice.
CHD2 belongs to a family of ATP-dependent chromatin remodeling proteins critical for the assembly and regulation of chromatin (Lamar and Carvill, 2018) . Mutations in members of this family have been associated with neurodevelopmental disorders, such as autism spectrum disorder, intellectual disability, and epilepsy (Carvill et al., 2013; Allen et al., 2013) . Mutations found in the CHD2 gene include partial or complete deletion of the gene as well as point mutations. All the mutations described are de novo and one mutant allele is enough to cause disease (Carvill et al., 2013; Allen et al., 2013; Suls et al., 2013) . Despite this correlation between CHD2 mutations and neurological diseases, very little is known about the role of this gene in brain development.
Studies in mice have shown that homozygous deletions of Chd2 produce a general growth delay and perinatal lethality, while heterozygous deletions affect neonatal viability and non-neoplastic lesions in most primary organs (Marfella et al., 2006) . More recently, it has been described that Chd2 knockdown promotes a premature neuronal differentiation during embryonic mouse cortical development due to a decrease in Pax6 + neural progenitor cells and an increase in Tbr2 + intermediate progenitor cells (Shen et al., 2015) . On the other hand, Chd2-knockdown zebrafish larvae exhibited seizurelike behavior with epileptiform discharges (Suls et al., 2013) . Additionally, CHD2 knockout in human embryonic stem cell-derived interneurons promotes a decrease in the number of neurons as well as a reduction in the neurite length (Meganathan et al., 2017) . These data together suggest Chd2 is critical for cortical development. However, more studies are needed to fully understand its role during neuronal differentiation and how mutations lead to neurodevelopmental disorders.
To better understand the role of Chd2, Kim et al. generated a Chd2 haploinsufficient mouse line (Kim et al., 2018) , which mimicked Chd2 loss in only one allele. First, the authors showed Chd2 expression through the adult mouse brain, in NeuN + neurons, GABAergic interneurons, and oligodendrocytes, as well as in the embryonic brain in the cortical plate, ventricular zone (VZ), and subventricular zone (SVZ), and in the ganglionic eminence (GE). Then, they analyzed the effect of Chd2 haploinsufficiency in the brain cytoarchitecture, but they did not find any laminar disorganization or differential thickness in the somatosensory cortex or in the hippocampus. However, they found a decrease in GABAergic interneurons in the somatosensory cortex postnatally and in adult Chd2 +/À mice. During embryonic development, they found a decrease in proliferative cells in the VZ/ SVZ as well as in Nkx2.1 + progenitor cells in the medial GE. They also found a reduction in the density of GABAergic neurons in the cortex. These data showed that Chd2 is critical during neuronal differentiation both in embryonic and adult brain.
To identify the molecular changes underlying these defects, they performed RNA sequencing of tissue from neocortex and medial GE of embryonic day (E)13.5 embryos as well as adult mouse hippocampus. This showed differential gene expression in genes associated with nervous system development, neuron differentiation, and neurogenesis in embryos. Similar categories were observed in adult hippocampus, with additional annotations such as synapse organization, neuronal activity and synaptic plasticity, transcriptional regulation and behavior, forebrain neurogenesis, RNA silencers, global regulators of the epigenome, cell adhesion molecules, and ion channels. Despite the presence of prominent phenotypic changes in GABAergic neurons, they observed many differentially expressed genes involved in glutamatergic synaptic function. Genes associated with epilepsy and autism spectrum disorders and other neurological disorders were also found. These results showed partial Chd2 loss affects the expression of a broad array of genes.
Next, whether Chd2 haploinsufficiency affects electrophysiological properties using patch-clamp recordings in CA1 hippocampal slices was studied. Chd2 +/À mouse pyramidal neurons showed an increase in action potential firing, a decrease in spike adaptation, and a sig-nificant increase in miniature excitatory postsynaptic current amplitudes and a decrease in miniature inhibitory postsynaptic current frequency. In addition, electroencephalogram recordings in the somatosensory neocortex revealed an increase in the alpha, delta, theta, and gamma frequency ranges in Chd2 +/À mice. Nevertheless, they did not find any overt convulsive seizures in 7 days of continuous monitoring in mice from both genotypes. These data showed that Chd2 affects both glutamatergic and GABAergic synaptic transmission in the adult hippocampus as well as cortical rhythmogenesis.
Finally, they analyzed whether Chd2 haploinsufficiency alters hippocampal-depended memory tasks using object location and recognition memory paradigms. The authors showed Chd2 +/À mice spent similar time exploring both objects when one new object was added to the cage or when one object was moved to a different location. Interestingly, similar memory defects were found in conditional Chd2 +/À mice where Chd2 was altered only in GABAergic progenitor cells (Nkx2.1 + cells). Moreover, when medial GE cells were injected, which expressed markers of interneurons after 45 days post-transplantation, spatial memory deficits improved in Chd2 +/À mice. Altogether, these data showed that Chd2 affects hippocampal memory due to loss of GABAergic interneurons.
As summarized in Figure 1 , the results presented by Kim and colleagues show that Chd2 is critical for embryonic and adult neuronal differentiation, synaptic properties, and memory, which partially explain the symptoms of CHD2 patients. Although there is a broad range of mutations affecting CHD2 in human, Chd2 +/À mice mimic a type of mutation that produces a small, truncated protein.
That could explain why the authors did not see some of the phenotypes observed in patients such as chronic seizures. Nevertheless, the authors clearly demonstrated that Chd2 is critical for GABAergic interneuron differentiation and a loss of these neurons leads to memory deficits. They also showed evidence that Chd2 may play a role in glutamatergic neuron differentiation and, in addition to the broad expression of Chd2 in the adult mouse brain, demonstrate that further analyses are needed to fully understand the role of Chd2 in specific neuronal subtypes. Moreover, additional experiments are needed to understand the molecular role of Chd2. Despite the gene expression changes in Chd2 +/À mice, it is unknown if these are direct targets and whether Chd2 binds chromatin/DNA to directly control gene expression. Furthermore, mouse models may not completely simulate human brain development (Rakic, 2009 ), e.g., specific subtypes of interneurons may have different origins in the mouse and human brain, and human brain has a larger expansion of cortical surface compared to mouse, among others. For this reason, studies of human tissues or in vitro analyses of patient-derived neurons or 3D organoids represent powerful complementary approaches to fully comprehend the etiology of CHD2 patients.
While there is still a long way to go, this study provides valuable information on understanding the role of Chd2 in the brain, which will be critical in the development of future therapeutics for Chd2-associated neurodevelopmental disorders.
